TSPAN8 as a Novel Emerging Therapeutic Target in Cancer for Monoclonal Antibody Therapy.
cancer
prognostic marker
tetraspanin 8
therapeutic target
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
03 03 2020
03 03 2020
Historique:
received:
03
02
2020
revised:
28
02
2020
accepted:
29
02
2020
entrez:
7
3
2020
pubmed:
7
3
2020
medline:
18
3
2021
Statut:
epublish
Résumé
Tetraspanin 8 (TSPAN8) is a member of the tetraspanin superfamily that forms TSPAN8-mediated protein complexes by interacting with themselves and other various cellular signaling molecules. These protein complexes help build tetraspanin-enriched microdomains (TEMs) that efficiently mediate intracellular signal transduction. In physiological conditions, TSPAN8 plays a vital role in the regulation of biological functions, including leukocyte trafficking, angiogenesis and wound repair. Recently, reports have increasingly shown the functional role and clinical relevance of TSPAN8 overexpression in the progression and metastasis of several cancers. In this review, we will highlight the physiological and pathophysiological roles of TSPAN8 in normal and cancer cells. Additionally, we will cover the current status of monoclonal antibodies specifically targeting TSPAN8 and the importance of TSPAN8 as an emerging therapeutic target in cancers for monoclonal antibody therapy.
Identifiants
pubmed: 32138170
pii: biom10030388
doi: 10.3390/biom10030388
pmc: PMC7175299
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Neoplasm Proteins
0
TSPAN8 protein, human
0
Tetraspanins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : the Bio& Medical Technology Development Program of the National Research Foundation
ID : NRF-2019M3E5D5065844
Pays : International
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest. The funders have no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Références
Biochem Biophys Res Commun. 2015 Mar 13;458(3):476-482
pubmed: 25680464
PLoS One. 2016 Aug 17;11(8):e0161017
pubmed: 27532105
Br J Cancer. 2012 Feb 28;106(5):923-30
pubmed: 22294188
Leukemia. 2012 Aug;26(8):1862-9
pubmed: 22333880
Cancer Res. 2017 May 1;77(9):2191-2196
pubmed: 28428282
PLoS One. 2015 Apr 27;10(4):e0125405
pubmed: 25915404
Proc Natl Acad Sci U S A. 1990 Sep;87(17):6833-7
pubmed: 2395876
Hybridoma. 1984 Winter;3(4):333-46
pubmed: 6396196
Cell Rep. 2014 Apr 24;7(2):527-538
pubmed: 24726368
J Pathol. 2019 Aug;248(4):421-437
pubmed: 30982971
World J Surg Oncol. 2012 May 21;10:92
pubmed: 22613496
Oncogenesis. 2017 Apr 3;6(4):e309
pubmed: 28368391
J Clin Oncol. 2010 Mar 1;28(7):1254-61
pubmed: 20100961
Gastric Cancer. 2016 Apr;19(2):370-380
pubmed: 25711980
Biochem Biophys Res Commun. 2015 Dec 25;468(4):774-80
pubmed: 26562525
Br J Cancer. 1999 Mar;79(7-8):1168-73
pubmed: 10098753
Oncogene. 2017 Jan 26;36(4):446-457
pubmed: 27375018
Nat Rev Cancer. 2003 May;3(5):362-74
pubmed: 12724734
Oncogene. 2016 Aug 25;35(34):4540-8
pubmed: 26804173
PLoS One. 2012;7(6):e38464
pubmed: 22679508
Oncology (Williston Park). 1998 Dec;12(12):1727
pubmed: 9874846
Head Neck. 2003 Oct;25(10):848-57
pubmed: 12966509
Surgery. 2014 Nov;156(5):1212-7
pubmed: 24890568
Nat Rev Cancer. 2009 Jan;9(1):40-55
pubmed: 19078974
Cell Rep. 2017 Mar 7;18(10):2343-2358
pubmed: 28273451
Br J Cancer. 2011 Jan 4;104(1):155-65
pubmed: 21081927
Med Sci Monit. 2018 Aug 17;24:5739-5747
pubmed: 30117494
Clin Cancer Res. 2001 Dec;7(12):4109-14
pubmed: 11751509
Mol Cell Neurosci. 2018 Sep;91:76-81
pubmed: 29631019
Cancer Med. 2019 Mar;8(3):1279-1288
pubmed: 30740913
Biochim Biophys Acta Mol Cell Res. 2018 Feb;1865(2):379-391
pubmed: 29138006
Clin Cancer Res. 2008 May 15;14(10):2918-26
pubmed: 18483358
J Cancer Res Clin Oncol. 2013 Nov;139(11):1835-43
pubmed: 24005419
Curr Clin Pharmacol. 2018;13(2):85-99
pubmed: 28799485
Oncotarget. 2016 Jun 28;7(26):40160-40173
pubmed: 27223087
Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1717-21
pubmed: 15533898
Cancer Res. 2006 Jul 15;66(14):7083-94
pubmed: 16849554
Oncogene. 2013 Apr 4;32(14):1772-83
pubmed: 22824799
Nat Commun. 2018 Apr 12;9(1):1423
pubmed: 29650964
Oncotarget. 2016 Sep 20;7(38):62377-62385
pubmed: 27566555
MAbs. 2020 Jan-Dec;12(1):1703531
pubmed: 31847708
J Cell Biol. 1998 Apr 6;141(1):267-80
pubmed: 9531564
Pathol Res Pract. 2014 May;210(5):285-90
pubmed: 24553302
Oncol Rep. 2015 Dec;34(6):3068-76
pubmed: 26370588
Int J Oncol. 2018 Feb;52(2):473-484
pubmed: 29345284
MAbs. 2019 Feb/Mar;11(2):219-238
pubmed: 30516432
Oncotarget. 2017 Mar 7;8(10):17140-17155
pubmed: 28188308
Int J Obes (Lond). 2011 Apr;35(4):605-17
pubmed: 20733586
Oncotarget. 2016 Jun 28;7(26):40630-40643
pubmed: 27270327
Cancer Res. 1996 Mar 15;56(6):1244-9
pubmed: 8640807
Genomics. 2008 Apr;91(4):326-34
pubmed: 18291621
Front Physiol. 2014 Sep 19;5:364
pubmed: 25285080
J Cell Mol Med. 2019 Apr;23(4):2549-2557
pubmed: 30701690
Hepatology. 2009 Feb;49(2):491-503
pubmed: 19065669
Genomics. 2005 Dec;86(6):674-84
pubmed: 16242907
Ann Transl Med. 2019 Sep;7(18):470
pubmed: 31700906
Biochem J. 2005 Jul 1;389(Pt 1):99-110
pubmed: 15725074
Somatic Cell Genet. 1979 Nov;5(6):957-71
pubmed: 94699
Clin Exp Metastasis. 2008;25(5):537-48
pubmed: 18365756
Int J Mol Sci. 2015 Mar 09;16(3):5363-74
pubmed: 25761241
J Hepatol. 2001 Nov;35(5):637-42
pubmed: 11690710
Oncol Rep. 2019 Nov;42(5):1957-1971
pubmed: 31432186
Mol Clin Oncol. 2016 Sep;5(3):231-236
pubmed: 27588187
Int J Cancer. 1998 Oct 23;79(5):509-16
pubmed: 9761121
Int J Urol. 2004 Feb;11(2):74-82
pubmed: 14706010
Pathol Res Pract. 2010 Sep 15;206(9):607-10
pubmed: 20547009
Oncol Rep. 1998 Nov-Dec;5(6):1507-11
pubmed: 9769396
Cancer Res. 2010 Oct 1;70(19):7674-83
pubmed: 20858717
Int J Clin Exp Med. 2015 Jun 15;8(6):8599-607
pubmed: 26309511
Br J Cancer. 2003 Jul 7;89(1):158-67
pubmed: 12838318
Methods Mol Med. 2000;40:267-79
pubmed: 21337095
J Oral Pathol Med. 2001 Feb;30(2):73-9
pubmed: 11168850
Eur J Cancer. 2013 Sep;49(13):2934-48
pubmed: 23683890
Cancer. 2003 Oct 15;98(8):1649-57
pubmed: 14534881
World J Gastroenterol. 2009 May 14;15(18):2270-6
pubmed: 19437569
Onco Targets Ther. 2018 Dec 13;11:8815-8822
pubmed: 30588007
Tumori. 2008 Jul-Aug;94(4):531-8
pubmed: 18822690
Lung Cancer. 2007 Jul;57(1):46-53
pubmed: 17350713
World J Gastroenterol. 2004 Aug 1;10(15):2245-9
pubmed: 15259074
Annu Rev Cell Dev Biol. 2003;19:397-422
pubmed: 14570575
Cancer Res. 1996 Apr 15;56(8):1751-5
pubmed: 8620488
FEBS Lett. 2016 Aug;590(16):2700-8
pubmed: 27339400
Cancer. 2001 Aug 1;92(3):542-8
pubmed: 11505398
Oncogene. 2019 May;38(20):3781-3793
pubmed: 30679790
Cancer Biother Radiopharm. 2016 Dec;31(10):353-359
pubmed: 27996312
Oncotarget. 2016 Oct 11;7(41):66344-66359
pubmed: 27572323
Clin Cancer Res. 1998 Jun;4(6):1507-10
pubmed: 9626469
Oncotarget. 2017 Mar 28;8(13):22034-22047
pubmed: 28423546
Nat Commun. 2019 Jun 28;10(1):2863
pubmed: 31253779
Int J Mol Med. 2015 Mar;35(3):798-802
pubmed: 25592989
Am J Pathol. 1998 Sep;153(3):973-83
pubmed: 9736046
Cancer Res. 1995 Dec 15;55(24):6040-4
pubmed: 8521390
Nat Rev Cancer. 2014 Jan;14(1):49-60
pubmed: 24505619
Clin Cancer Res. 2005 Apr 15;11(8):2840-52
pubmed: 15837731
Cancers (Basel). 2019 Feb 03;11(2):
pubmed: 30769765